Oseltamivir: a clinical and pharmacological perspective (Q34515436)

2 August 2017

1 reference

title

Oseltamivir: a clinical and pharmacological perspective (English)

1 reference

2 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Doucette KE

1

1 reference

2 August 2017

Aoki FY

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

Expert Opinion on Pharmacotherapy

2 August 2017

published in

1 reference

2 August 2017

volume

2

1 reference

2 August 2017

issue

10

1 reference

2 August 2017

page(s)

1671-1683

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

2 August 2017

1 reference

The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Influenza virus M2 protein has ion channel activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Emergence and apparent transmission of rimantadine-resistant influenza A virus in families

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

The neuraminidase of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Rational design of potent sialidase-based inhibitors of influenza virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Site-directed mutagenesis of catalytic residues of influenza virus neuraminidase as an aid to drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Influenza A viruses lacking sialidase activity can undergo multiple cycles of replication in cell culture, eggs, or mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

GS4071 is a slow-binding inhibitor of influenza neuraminidase from both A and B strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Oral oseltamivir treatment of influenza in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Oseltamivir: a review of its use in influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

Resistance of influenza viruses to neuraminidase inhibitors--a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1671

10.1517/14656566.2.10.1671

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference